Contraline, a pioneering biotechnology firm backed by Google Ventures, has successfully closed a substantial $92.5 million Series B financing round.…
Read More
ASCO 2026 Delivers Promising Advances and Crucial Data in Blood Cancer Treatment
The 2026 American Society of Clinical Oncology (ASCO) conference, a cornerstone event for oncological advancements, has concluded, leaving a significant…
Read More
Lilly’s $7bn Acquisition of Kelonia Bears Fruit as In Vivo Cell Therapies Show Significant Promise at ASCO 2026
The American Society for Clinical Oncology (ASCO) meeting in 2026, a cornerstone event for oncological advancements, has concluded, leaving behind…
Read More
ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma – Pharmaceutical Technology
The rapidly evolving landscape of multiple myeloma treatment is witnessing a pivotal moment with the emergence of in vivo chimeric…
Read More
US FDA Grants Priority Review to Bristol Myers Squibb’s Camzyos for Adolescent Patients with Obstructive Hypertrophic Cardiomyopathy
The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental new drug application (sNDA) for Camzyos…
Read More
Brinsupri Poised to Redefine Bronchiectasis Treatment Standards Following Robust ATS 2026 Showcase
The landscape of non-cystic fibrosis bronchiectasis (NCFB) treatment is undergoing a significant transformation with the emergence of Brinsupri (brensocatib), a…
Read More
Salesforce lands 140 life sciences clients, pitches ‘headless’ AI to pharma
In a strategic maneuver that underscores the intensifying competition in the life sciences technology sector, Salesforce has announced that over…
Read More
Revolution Medicines’ Daraxonrasib Achieves Landmark Survival Extension in Pancreatic Cancer, Heralding New Era of Targeted Therapy
The field is ecstatic about the prospect of a targeted therapy meaningfully extending overall survival in pancreatic cancer. The 2026…
Read More
ASCO 2026: Lung Cancer Landscape Ignites with Promising Bispecifics, Targeted Therapies, and Extended Survival Data
The annual American Society of Clinical Oncology (ASCO) congress, a cornerstone event for the global oncology community, convened in Chicago,…
Read More
Eli Lilly and Company Secures Global Rights to Hanmi Pharm’s Sonefpeglutide in Potential $1.26 Billion Deal
Eli Lilly and Company has forged a significant licensing agreement with South Korean biopharmaceutical firm Hanmi Pharm, potentially worth up…
Read More
